Why TG Therapeutics Stock Jumped 10% Today

MarketsMotley Fool

What happened

After reporting early-stage trial results for one of the cancer drugs in its pipeline, TG Therapeutics (NASDAQ: TGTX) jumped 9.9% on Wednesday.

Continue Reading Below

So what

The clinical-stage biotech stock has previously provided interesting trial data for TG-1101, or ublituximab, when used with AbbVie's (NYSE: ABBV) and Johnson & Johnson's (NYSE: JNJ) Imbruvica in leukemia patients. Today, it unveiled positive results from a trial evaluating another drug, umbralisib.

Specifically, umbralisib was clinically active with 85% of relapsed or refractory CLL patients achieving an objective response and 53% of patients with relapsed or refractory follicular lymphoma achieving an objective response, including two patients with a complete response.

The data could indicate that results expected later this year from a trial evaluating the use of umbralisib and ublituximab together in refractory CLL will succeed. The two-drug combination (U2) is being compared head-to-head against Gazyva and chlorambucil, a chemotherapy. If TG Therapeutics' doublet outperforms Gazyva, then TG Therapeutics' plan is to discuss the chances of approval with the Food and Drug Administration.

Now what

Ublituximab's overall response rate alongside Imbruvica is 81%, and if adding umbralisib to it can improve upon treatment, this could be a nine-figure opportunity for the company. For comparison, Imbruvica is a multibillion-dollar drug and Gazyva sales were about $300 million in 2017, at current exchange rates.

It's anyone's guess if final trial data that could support an FDA OK will be as good as we've seen so far and if the FDA will provide an easy pathway to market. Nevertheless, the data's good enough right now for me to think that this company might be worth more than its current $978 million market cap if trials go its way.

10 stocks we like better than TG TherapeuticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and TG Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 5, 2018

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Johnson & Johnson. The Motley Fool has a disclosure policy.